Gilead Sciences Inc. plans to pluck the steadily ripening mid-cap Myogen Inc. for about $2.5 billion, a takeover that would add the Phase III headliner ambrisentan for pulmonary arterial hypertension to Gilead's pipeline, as well as the less celebrated - but potentially at least as valuable - darusentan for resistant high blood pressure. (BioWorld Today) Read More
